2448-2449 / 2953
What were the problems with these trials ?
•
Recruitment of patients with low risk of LN mets (GETUG)
•
Low doses of RT to prostate and pelvis approx. 66-70GY
and 46-48Gy
62
•
Inadequate treatment of some LN groups
•
Interaction with scheduling of hormone treatment
(RTOG)
•
Some favourable subgroup analyses for LN RT